Uro Gen Pharma Ltd. URGN
We take great care to ensure that the data presented and summarized in this overview for UroGen Pharma Ltd. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding URGN
View all-
Rtw Investments, LP New York, NY4.54MShares$87.2 Million0.96% of portfolio
-
Ubs Asset Management Americas Inc Chicago, IL4.36MShares$83.7 Million0.01% of portfolio
-
Ra Capital Management, L.P. Boston, MA3.21MShares$61.6 Million0.74% of portfolio
-
Jefferies Financial Group Inc. New York, NY2.2MShares$42.2 Million0.27% of portfolio
-
Black Rock Inc. New York, NY2.19MShares$42.1 Million0.0% of portfolio
-
Vestal Point Capital, LP New York, NY2.15MShares$41.3 Million1.7% of portfolio
-
Toronto Dominion Bank Toronto, Ontario, A61.75MShares$33.6 Million0.04% of portfolio
-
Acorn Capital Advisors, LLC New York, NY1.52MShares$29.1 Million11.67% of portfolio
-
Silverarc Capital Management, LLC1.38MShares$26.5 Million3.72% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT1.36MShares$26.2 Million0.68% of portfolio
Latest Institutional Activity in URGN
Top Purchases
Top Sells
About URGN
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
Insider Transactions at URGN
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 11
2025
|
Mark Schoenberg Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
10,000
-6.32%
|
$170,000
$17.69 P/Share
|
|
Jul 28
2025
|
Mark Schoenberg Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,149
-3.15%
|
$97,831
$19.14 P/Share
|
|
Jul 28
2025
|
Mark Schoenberg Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+5.77%
|
-
|
|
Jul 28
2025
|
Jason Drew Smith General Counsel |
SELL
Open market or private sale
|
Direct |
7,522
-15.35%
|
$142,918
$19.14 P/Share
|
|
Jul 28
2025
|
Jason Drew Smith General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
16,500
+25.19%
|
-
|
|
Jun 09
2025
|
Mark Schoenberg Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,162
-3.26%
|
$36,134
$7.37 P/Share
|
|
Jun 08
2025
|
Mark Schoenberg Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+5.93%
|
-
|
|
Jan 31
2025
|
Jason Drew Smith General Counsel |
SELL
Open market or private sale
|
Direct |
7,379
-7.5%
|
$81,169
$11.14 P/Share
|
|
Jan 31
2025
|
Jason Drew Smith General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
14,667
+12.84%
|
-
|
|
Jan 31
2025
|
Mark Schoenberg Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,551
-1.02%
|
$50,061
$11.14 P/Share
|
|
Jan 31
2025
|
Mark Schoenberg Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+1.75%
|
-
|
|
Sep 09
2024
|
Dong Kim Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+6.21%
|
-
|
|
Sep 09
2024
|
Jason Drew Smith General Counsel |
SELL
Open market or private sale
|
Direct |
1,521
-5.69%
|
$19,773
$13.08 P/Share
|
|
Sep 09
2024
|
Jason Drew Smith General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
3,333
+11.08%
|
-
|
|
Sep 09
2024
|
Mark Schoenberg Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
859
-0.59%
|
$11,167
$13.08 P/Share
|
|
Sep 09
2024
|
Mark Schoenberg Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,666
+1.13%
|
-
|
|
Jun 10
2024
|
Mark Schoenberg Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,153
-3.45%
|
$66,989
$13.08 P/Share
|
|
Jun 10
2024
|
Mark Schoenberg Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+6.27%
|
-
|
|
Mar 18
2024
|
Mark Schoenberg Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
12,000
-7.92%
|
$168,000
$14.05 P/Share
|
|
Jan 31
2024
|
Jason Drew Smith General Counsel |
SELL
Open market or private sale
|
Direct |
4,993
-6.82%
|
$74,895
$15.74 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 66.7K shares |
|---|
| Open market or private sale | 42.1K shares |
|---|